Tags

Type your tag names separated by a space and hit enter

Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
Dement Geriatr Cogn Disord. 2002; 13(1):33-9.DG

Abstract

To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.

Authors+Show Affiliations

Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan. shunya@post.harvard.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11731713

Citation

Ikeda, Shunya, et al. "Economic Evaluation of Donepezil Treatment for Alzheimer's Disease in Japan." Dementia and Geriatric Cognitive Disorders, vol. 13, no. 1, 2002, pp. 33-9.
Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord. 2002;13(1):33-9.
Ikeda, S., Yamada, Y., & Ikegami, N. (2002). Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dementia and Geriatric Cognitive Disorders, 13(1), 33-9.
Ikeda S, Yamada Y, Ikegami N. Economic Evaluation of Donepezil Treatment for Alzheimer's Disease in Japan. Dement Geriatr Cogn Disord. 2002;13(1):33-9. PubMed PMID: 11731713.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. AU - Ikeda,Shunya, AU - Yamada,Yukari, AU - Ikegami,Naoki, PY - 2001/12/4/pubmed PY - 2002/1/31/medline PY - 2001/12/4/entrez SP - 33 EP - 9 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 13 IS - 1 N2 - To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy. SN - 1420-8008 UR - https://www.unboundmedicine.com/medline/citation/11731713/Economic_evaluation_of_donepezil_treatment_for_Alzheimer's_disease_in_Japan_ L2 - https://www.karger.com?DOI=10.1159/000048631 DB - PRIME DP - Unbound Medicine ER -